Inclusion debt. The compounding cost of designing clinical development without lived-experience input.
Every phase of development that ships without adequate subgroup evidence adds cost and risk to the next.
Inclusion debt does not present as a moral problem. It presents as a cash-flow and timeline problem: an unexpected protocol amendment, a JCA PICO the file cannot answer, a subgroup performance question a notified body cannot let past, a Trust that will not procure without an accessibility statement, a post-market signal that surfaces two years after launch and forces a label restriction.
Each of those events looks, in the moment, like an operational hiccup. Together, over the lifetime of a programme, they are the interest payments on a debt taken out at protocol design.
The framing matters because it changes who owns the problem inside a sponsor. If inclusion is a moral obligation, it sits with the DE&I officer, the medical affairs patient partnership lead, or the head of PPI. If inclusion debt is a cash-flow risk, it sits with the CFO, the head of regulatory affairs, the head of market access, and the programme lead. Those are the people who can authorise the fixed-scope engagements that pay the debt down early.
Every one of these is an interest payment on inclusion debt taken out earlier in the programme.
Once you see the pattern, it is hard to unsee. These are not six different problems. They are six different presentations of the same problem, at six different points in the development timeline.
Protocol amendments driven by recruitment failure
The trial cannot enrol the population the protocol requires, so eligibility criteria are widened, or sites are added, or endpoints are softened. £353,000 to £535,000 per major amendment. 3 to 6 months of delay per amendment.
Screen-fails in specific subgroups
Recruited participants disproportionately fail screening in the very subgroups the protocol under-planned for. The sponsor pays for the screening in full and does not get the enrolment.
HTA queries that stop the clock
EU JCA, NICE and G-BA reviewers now ask, explicitly, where the subgroup evidence is. A file that does not have it either loses PICOs or triggers extension requests. Every day of delay after regulatory approval costs a sponsor around $800,000 in unrealised prescription-drug sales.
Label limitations
Regulators approve the product but restrict the label to the population actually studied. The addressable market shrinks, sometimes materially, and every future expansion requires a new trial in the missing population.
NHS DTAC deferrals and NICE ESF deferrals
Digital-health and SaMD files that cannot answer the inequality-consideration and dataset-diversity questions are deferred by NHS procurement or NICE reviewers. Deferral is not rejection, but it is a 3 to 12 month reset with no revenue.
Post-market failures
Under UK PMS 2025 and EU MDR Annex XIV, manufacturers must now actively look for the subgroup issue their pivotal file did not catch. If the regulator finds it first, it becomes an enforcement matter, not a routine PMS finding.
Inclusion debt shows up on three different counters, depending on who you are.
in unrealised prescription-drug sales for every day of HTA delay after regulatory approval. $24 million a month, $144 million for a six-month slip.
the average cost of a single major protocol amendment driven by recruitment failure. Every one an inclusion-debt event caught downstream instead of upstream. Delays of 3 to 6 months follow.
the annual cost of health inequality in England: £4.8bn in avoidable treatment and £31bn in lost productivity. The counter the NHS itself pays.
The earlier inclusion debt is paid down, the smaller the payment.
The same intervention costs roughly one order of magnitude more at each subsequent stage of the development timeline. This is the single most important reason to move inclusion evidence upstream.
Inclusion debt is not the same as technical debt, but it behaves like it.
The mental model is transferable. If you have worked with technical debt in a software organisation, you already understand inclusion debt in a clinical-development organisation.
Technical debt
Every shortcut in code, every skipped test, every "we will refactor this later", accrues. Interest is paid in slower feature velocity, more bugs in production, and eventually a rewrite.
Fix at design time: cheap. Fix at production: expensive. Fix at customer complaint: most expensive.
Inclusion debt
Every population not consulted, every subgroup not analysed, every "we will address this in Phase III", accrues. Interest is paid in protocol amendments, HTA queries, DTAC deferrals, and post-market signals.
Fix at protocol design: cheap. Fix at HTA: expensive. Fix at MHRA enforcement: most expensive.
Free deep-dives on inclusion debt in specific frameworks.
UK Inclusion & Diversity Plan Guide
What the MHRA Inclusion and Diversity Plan asks for in practice, section by section, with worked examples for how to answer each requirement.
Download the guide →Germany Patient Evidence Guide
Patient-evidence expectations for G-BA reappraisals and the German JCA pathway, with the specific PICO patient-input dimensions German assessors ask about.
Download the guide →The Frequency of Exclusion
Insights direct from our UK panel on where healthcare exclusion actually shows up, and how often. An interactive report built from Equity Engine data.
Explore the report →Take the Regulatory Readiness Scorecard.
Twenty questions, six domains. A plain-English diagnosis of the inclusion debt your programme is carrying, and the specific fixed-scope engagement that pays it down at the cheapest point.